Movement Alert｜BIOCYTOGEN-B Rises 5.07% in Regular Trading, H1 Net Profit Expected to Surge Over 400% with Continued Institutional Accumulation

Market Focus08-13

On August 13, BIOCYTOGEN-B rose 5.07% in regular trading, trading at 70.25 HKD/share, with turnover of HKD 160 million.

On the news front, the company previously issued an H1 earnings forecast projecting revenue of RMB 936-946 million, up 51-52% year-on-year, and net profit attributable to shareholders of RMB 236-246 million, representing growth of 392-413%. The strong guidance follows Q1 results showing revenue of RMB 433 million (up 74% YoY) and net profit of RMB 104 million, a turnaround from a loss in the prior year.

Institutional accumulation has continued, with E Fund raising its stake to 10.0% through multiple purchases at prices ranging from HKD 40-57 per share, while Fullgoal Fund increased its holding to 8.23%. The company also secured a global strategic partnership with Whitehawk Therapeutics covering multiple bispecific antibody-drug conjugate programs, further validating its RenLite platform capabilities and dual-engine growth from animal models and antibody development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125512975?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 13:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125512975","market":"us","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Rises 5.07% in Regular Trading, H1 Net Profit Expected to Surge Over 400% with Continued Institutional Accumulation","media":"Market Focus","content":"<p><p>On August 13, BIOCYTOGEN-B rose 5.07% in regular trading, trading at 70.25 HKD/share, with turnover of HKD 160 million.</p><p>On the news front, the company previously issued an H1 earnings forecast projecting revenue of RMB 936-946 million, up 51-52% year-on-year, and net profit attributable to shareholders of RMB 236-246 million, representing growth of 392-413%. The strong guidance follows Q1 results showing revenue of RMB 433 million (up 74% YoY) and net profit of RMB 104 million, a turnaround from a loss in the prior year.</p><p>Institutional accumulation has continued, with E Fund raising its stake to 10.0% through multiple purchases at prices ranging from HKD 40-57 per share, while Fullgoal Fund increased its holding to 8.23%. The company also secured a global strategic partnership with Whitehawk Therapeutics covering multiple bispecific antibody-drug conjugate programs, further validating its RenLite platform capabilities and dual-engine growth from animal models and antibody development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Rises 5.07% in Regular Trading, H1 Net Profit Expected to Surge Over 400% with Continued Institutional Accumulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Rises 5.07% in Regular Trading, H1 Net Profit Expected to Surge Over 400% with Continued Institutional Accumulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-13 13:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 13, BIOCYTOGEN-B rose 5.07% in regular trading, trading at 70.25 HKD/share, with turnover of HKD 160 million.</p><p>On the news front, the company previously issued an H1 earnings forecast projecting revenue of RMB 936-946 million, up 51-52% year-on-year, and net profit attributable to shareholders of RMB 236-246 million, representing growth of 392-413%. The strong guidance follows Q1 results showing revenue of RMB 433 million (up 74% YoY) and net profit of RMB 104 million, a turnaround from a loss in the prior year.</p><p>Institutional accumulation has continued, with E Fund raising its stake to 10.0% through multiple purchases at prices ranging from HKD 40-57 per share, while Fullgoal Fund increased its holding to 8.23%. The company also secured a global strategic partnership with Whitehawk Therapeutics covering multiple bispecific antibody-drug conjugate programs, further validating its RenLite platform capabilities and dual-engine growth from animal models and antibody development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1125512975","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125512975","pubTimestamp":1786598964,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 13, BIOCYTOGEN-B rose 5.07% in regular trading, trading at 70.25 HKD/share, with turnover of HKD 160 million.On the news front, the company previously issued an H1 earnings forecast...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势预警|BIOCYTOGEN-B常规交易大涨5.07%，H1净利有望飙升超400%，机构持续累积","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On August 13, BIOCYTOGEN-B rose 5.07% in regular trading, trading at 70.25 HKD/share, with turnover of HKD 160 million.On the news front, the company previously issued an H1 earnings forecast projecting revenue of RMB 936-946 million, up 51-52% year-on-year, and net profit attributable to shareholders of RMB 236-246 million, representing growth of 392-413%. The strong guidance follows Q1 results showing revenue of RMB 433 million (up 74% YoY) and net profit of RMB 104 million, a turnaround from a loss in the prior year.Institutional accumulation has continued, with E Fund raising its stake to 10.0% through multiple purchases at prices ranging from HKD 40-57 per share, while Fullgoal Fund increased its holding to 8.23%. The company also secured a global strategic partnership with Whitehawk Therapeutics covering multiple bispecific antibody-drug conjugate programs, further validating its RenLite platform capabilities and dual-engine growth from animal models and antibody development.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125512975","isCrawlerRequest":true}